However, the clinical use of VEGF-targeted therapies is hindered by the potential side effects such as hypertension, proteinuria, bleeding, and cardiovascular complications in achieving optimal therapeutic concentrations (44,45). The gene discussed is VEGFA; the disease is hypertensive disorder.